MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Merck & Co Inc.

Cerrado

SectorSanidad

86.61 -0.51

Resumen

Variación precio

24h

Actual

Mínimo

85.39

Máximo

87.02

Métricas clave

By Trading Economics

Ingresos

583M

3.7B

Ventas

-1B

16B

P/B

Media del Sector

13.318

63.778

BPA

1.72

Rentabilidad por dividendo

3.61

Margen de beneficios

23.963

Empleados

73,000

EBITDA

1.3B

6.9B

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+28.42% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

3.61%

2.39%

Próximas Ganancias

24 abr 2025

Fecha Próximo Dividendo

7 abr 2025

Próxima Fecha de Ex Dividendo

16 jun 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-26B

227B

Apertura anterior

87.12

Cierre anterior

86.61

Noticias sobre sentimiento de mercado

By Acuity

39%

61%

145 / 386 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

Merck & Co Inc. Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

4 feb 2025, 12:33 UTC

Ganancias

Merck 4Q Earnings Rise; 2025 Outlook Hits Shares -- Update

4 feb 2025, 11:57 UTC

Ganancias

Merck 4Q Sales Increase Results in Swing to Profit

24 mar 2025, 05:00 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Chipotle and 4 More Buyback Stocks for a Down Market -- Barrons.com

5 mar 2025, 19:42 UTC

Principales Noticias

New Version of Merck's Blockbuster Cancer Drug Threatened by Patent Battle -- Update

5 mar 2025, 10:30 UTC

Principales Noticias

New Version of Merck's Blockbuster Cancer Drug Threatened by Patent Battle -- WSJ

5 feb 2025, 12:00 UTC

Principales Noticias

Merck Is Suffering From a Classic Pharma Problem -- Heard on the Street -- WSJ

4 feb 2025, 14:48 UTC

Ganancias

Merck Stock Plummets 10% As Gardasil Dynamics, 2025 Guidance Weigh On Shares -- IBD

4 feb 2025, 11:51 UTC

Ganancias

Merck's Soft Guidance Offsets Better-Than-Expected Fourth-Quarter Earnings -- MarketWatch

4 feb 2025, 11:50 UTC

Ganancias

Merck Stock Tumbles on Weak Guidance and Gardasil Sales Slump -- Barrons.com

4 feb 2025, 11:31 UTC

Ganancias

Merck 4Q Gardasil/Gardasil 9 Sales Down 17% >MRK

4 feb 2025, 11:31 UTC

Ganancias

Merck 4Q Gardasil/Gardasil 9 Sales $1.55B >MRK

4 feb 2025, 11:31 UTC

Ganancias

Merck 4Q Januvia/Janumet Sales Down 38% >MRK

4 feb 2025, 11:31 UTC

Ganancias

Merck 4Q Januvia/Janumet Sales $487M >MRK

4 feb 2025, 11:30 UTC

Ganancias

Merck 4Q Keytruda Sales Up 19% >MRK

4 feb 2025, 11:30 UTC

Ganancias

Merck 4Q Keytruda Sales $7.84B >MRK

4 feb 2025, 11:30 UTC

Ganancias

Merck 4Q Pharmaceutical Sales Up 7% >MRK

4 feb 2025, 11:30 UTC

Ganancias

Merck 4Q Pharmaceutical Sales $14.04B >MRK

4 feb 2025, 11:30 UTC

Ganancias

Merck Sees FY Adj EPS $8.88-Adj EPS $9.03 >MRK

4 feb 2025, 11:30 UTC

Ganancias

Merck: Anticipate Strong Growth in Back Half of 2025, as Well as in Both 2026 and 2027 >MRK

4 feb 2025, 11:30 UTC

Ganancias

Merck Sees FY Rev $64.1B-$65.6B >MRK

4 feb 2025, 11:30 UTC

Ganancias

Merck: Believe Temporary Pause Will Facilitate a More Rapid Reduction of Excess Inventory >MRK

4 feb 2025, 11:30 UTC

Ganancias

Merck: Expect Strength in Oncology and Contributions From Ongoing and New Launches of Important Products in Both Human and Animal Health Businesses to More Than Offset GARDASIL Headwind >MRK

4 feb 2025, 11:30 UTC

Ganancias

Merck 4Q Adj EPS $1.72 >MRK

4 feb 2025, 11:30 UTC

Ganancias

Merck: Gardasil Market Dynamics in China Do Not in Any Way Diminish the Confidence Co. Has in the Business >MRK

4 feb 2025, 11:30 UTC

Ganancias

Merck 4Q Net $3.74B >MRK

4 feb 2025, 11:30 UTC

Ganancias

Merck: Excluding Sales of Gardasil in China in Both 2024 and 2025, Expect Strong 2025 Growth Between 7%-9% (Ex-FX) Driven by Continued Strength in Oncology and Animal Health as Well as Contributions From New Product Launches >MRK

4 feb 2025, 11:30 UTC

Ganancias

Merck: Sales Outlook Reflects Reassessment of Market for Gardasil/Gardasil 9 in China and Decision to Temporarily Pause Shipments Until at Least Mid-Year >MRK

4 feb 2025, 11:30 UTC

Ganancias

Merck Sees FY25 Sales $64.1B-$65.6B >MRK

4 feb 2025, 11:30 UTC

Ganancias

Merck: Decline in 4Q Januvia/Janumet Sales Primarily Due to Lower Pricing in U.S., and Ongoing Generic Competition in Many International Markets and Supply Constraints in China >MRK

4 feb 2025, 11:30 UTC

Ganancias

Merck 4Q Winrevair Sales $200M >MRK

Comparación entre iguales

Cambio de precio

Merck & Co Inc. previsión

Precio Objetivo

By TipRanks

28.42% repunte

Estimación a 12 Meses

Media 111.88 USD  28.42%

Máximo 138 USD

Mínimo 95 USD

De acuerdo con 17 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Merck & Co Inc. Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

17 ratings

11

Comprar

6

Mantener

0

Vender

Puntuación técnica

By Trading Central

87.08 / 93.84Soporte y Resistencia

Corto Plazo

Strong Bearish Evidence

Medio plazo

Bullish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

145 / 386 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Merck & Co Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. vIt has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. It also has licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.